Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis

Lee, Seon Heui; Hong, Jin Hyuk; Cho, Kyoung Hee; Noh, Jin-Won; Cho, Hyun-Jai

doi:10.1186/s13287-016-0415-z

Stem Cell Research & Therapy

Table 1 Study characteristics

From: Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis

Author	Year	Country	Timing of cell injection	Cell injection (n)	Control (n)	Total patient (n)	Cell type	Cell delivery route	Cell preparation	No. of injected cells	Follow-up (months)
Assmus et al. [9]	2014	Germany	After PCI	101	103	204	MNC	IC	Ficoll gradient	1 × 10⁶	60
Benedek et al. [10]	2014	Romania	After PCI	9	9	18	MNC	IC	Concentration by apheresis	1.66 ± 0.32 × 10⁹	48
Lee et al. [11]	2014	Korea	After PCI	30	28	58	MSC	IC	1-month culture	7.2 ± 0.90 × 10⁷	6
Robbers et al. [12]	2014	Netherlands	After PCI	30	45	75	BM-MNC/PB-MNC	IC	Lymphoprep™	296 ± 164 × 10⁶	4
Gao et al. [13]	2013	China	After PCI	21	22	43	MSC	IC	2-week culture	3.08 ± 0.52 x 10⁶	6, 12, 24
Surder et al. [14]	2013	Switzerland	After PCI	65	67	132	MNC	IC	Density gradient	5 × 10⁷ - 5 × 10⁸	4
Wohrle et al. [15]	2013	Germany	After PCI	29	13	42	MNC	IC	Ficoll gradient	324 × 10⁶	6, 12, 24, 36
Jazi et al. [16]	2012	Iran	After PCI	16	16	32	MNC	IC	Ficoll gradient	24.6 ± 8.4 × 10⁸	6
Kang et al. [17]	2012	Korea	After PCI	57	60	117	PB-MNC	IC	G-CSF/leukapheresis	1.1 ± 0.5 × 10⁹	6, 24, 60
Skalicka et al. [18]	2012	Czech	After PCI	17	10	27	MNC	IC	Gelfusine	26.4 × 10⁸	4, 24
Traverse et al. [19]	2012	USA	After PCI	79	41	120	MNC	IC	Sepax®	150 × 10⁶	6
Colombo et al. [20]	2011	Italy	After PCI	5	5	10	CD133+ MNC	IC	CD133 by CliniMACS®	4.9-135 × 10⁶	12
Hirsch et al. [21]	2011	Netherlands	After PCI	69	65	134	MNC	IC	Lymphoprep™	296 ± 164 × 10⁶	4
Pena-Duque et al. [22]	2011	Mexico	After PCI	4	4	8	MNC	IC	Sepax®	1 ~ 2 × 10⁶ CD34+	6
Plewka et al. [23]	2011	Poland	After PCI	40	20	60	MNC	IC	Safe Flow®	1.44 ± 0.49 × 10⁸	24
Quyyumi et al. [24]	2011	USA	After PCI	16	15	31	CD34+ MNC	IC	Isolex 300i®	5 × 10⁶	6, 12
Roncalli et al. [25]	2011	France	After PCI	52	49	101	MNC	IC	Ficoll	98 ± 8.7 × 10⁶	3
Srimahachota et al. [26]	2011	Thailand	After PCI	11	12	23	MNC	IC	Isoprep®	420 ± 221 × 10⁶	6
Turan et al. [27]	2011	Germany	After PCI	38	18	56	MNC	IC	Point of Care system	1 × 10⁶	3, 12
Yerebakan et al. [28]	2011	Germany	During CABG	20	20	40	CD133+ MNC	IM	CD133 by CliniMACS®	6.0 × 10⁶	108
Grajek et al. [29]	2010	Poland	After PCI	31	14	45	MNC	IC	Ficoll gradient	4.1 ± 1.8 × 10⁸	3, 6, 12
Mansour et al. [30]	2010	Canada	After PCI	14		14	CD133+ MNC	IC	CliniMACS®	10 × 10⁶-	4
Piepoli et al. [31]	2010	Italy	After PCI	19	19	38	MNC	IC	Ficoll gradient	418 × 10⁶	3, 6, 12
Traverse et al. [32]	2010	USA	After PCI	30	10	40	MNC	IC	Ficoll gradient	100 × 10⁶	6
Wohrle et al. [33]	2010	Germany	After PCI	29	13	42	MNC	IC	Ficoll gradient	381 ± 130 × 10⁶	6
Cao et al. [34]	2009	USA	After PCI	41	45	86	MNC	IC	Lymphoprep™	5 ± 1.2 × 10⁷	48
Hare et al. [35]	2009	USA	After PCI	39	21	60	MSC (allogeneic)	IV	1-month culture	0.5 ~ 5 × 10⁶	6
Nogueira et al. [36]	2009	Brazil	After PCI	14	6	20	MNC	IC	Ficoll gradient	10 × 10⁶	6
Yao et al. [37]	2009	China	After PCI	12	12	24	MNC	IC	Ficoll gradient	1.9 ± 1.3 × 10⁸	6, 12
Huikuri et al. [38]	2008	Finland	After PCI	40	40	80	MNC	IC	Ficoll gradient	4.02 ± 1.96 × 10⁶	6
Meluzin et al. [39]	2008	Czech	After PCI	20	20	40	MNC	IC	Histopaque1077	1-10 × 10⁷	3, 6, 12
Panovsky et al. [40]	2008	Czech	After PCI	13	17	30	MNC	IC	Histopaque1077	1-10 × 10⁸	3
de Lezo et al. [41]	2007	Spain	After PCI	10	10	20	MNC	IC	Ficoll gradient	9 ± 3 × 10⁸	3
Ge et al. [42]	2006	China	After PCI	10	10	20	MNC	IC	Ficoll gradient	4 × 10⁷	6
Janssens et al. [43]	2006	Belgium	After PCI	33	34	67	MNC	IC	Ficoll gradient	172 ± 72 × 10⁶	4
Lunde et al. [44]	2006	Norway	After PCI	47	50	97	MNC	IC	Ficoll gradient	68 × 10⁶	6, 36
Meluzin et al. [45]	2006	Czech	After PCI	22	22	44	MNC	IC	Histopaque1077	1x10⁷ -1 × 10⁸	3
Schachinger et al. [46]	2006	Germany	After PCI	101	103	204	MNC	IC	Ficoll gradient	236 ± 174 × 10⁶	24
Karpov et al. [47]	2005	Russia	After PCI	22	22	44	MNC	IC	Histopaque1077	88.5 ± 49.2 × 10⁶	6
Ruan et al. [48]	2005	China	After PCI	9	11	20	MNC	IC	Not described	Not described	6
Chen et al. [49]	2004	China	After PCI	34	35	69	MSC	IC	10-day culture	2-5 × 10⁶	3, 6
Kang et al. [50]	2004	Korea	After PCI	6	7	13	PB-MNC	IC	G-CSF/leukapheresis	1 × 10⁹	6, 24
Wollert et al. [51]	2004	Germany	After PCI	30	30	60	MNC	IC	4 % gelatine-polysuccinate	24.6 ± 9.4 × 10⁸	6, 18, 60

Included studies were all randomized clinical trials (RCTs). Plus-minus value indicates mean ± SE
PCI percutaneous coronary intervention, MNC mononuclear cell, IC intracoronary cell infusion, BM-MNC bone marrow-derived mononuclear cell, PB-MNC peripheral blood-derived mononuclear cell, G-CSF granulocyte colony-stimulating factor, CABG coronary artery bypass graft, IM intramyocardial cell injection, IV intravenous cell infusion, MSC mesenchymal stromal cell

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com